Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Evaluate the Effects of 177Lu-DOTATATE in Patients With Unresectable and Progressive Rare Metastatic Endocrine Carcinomas: Medullary Thyroid Cancer, Parathyroid Carcinoma, Pituitary Carcinoma, and Malignant Pheochromocytoma/Paraganglioma

NCT04106843 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT04106843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04106843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Evaluate the Effects of 177Lu-DOTATATE in Patients With Unresectable and Progressive Rare Metastatic Endocrine Carcinomas: Medullary Thyroid Cancer, Parathyroid Carcinoma, Pituitary Carcinoma, and Malignant Pheochromocytoma/Paraganglioma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Withdrawn
Start date
June 13, 2019
Completion date
September 3, 2020
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced adrenal gland pheochromocytoma, locally advanced paraganglioma, metastatic adrenal gland pheochromocytoma, metastatic paraganglioma, metastatic parathyroid gland carcinoma, pituitary gland carcinoma, somatostatin receptor positive, stage iii thyroid gland medullary carcinoma ajcc v8, stage iv thyroid gland medullary carcinoma ajcc v8, stage iva thyroid gland medullary carcinoma ajcc v8, stage ivb thyroid gland medullary carcinoma ajcc v8, stage ivc thyroid gland medullary carcinoma ajcc v8, unresectable adrenal gland pheochromocytoma, unresectable paraganglioma